Skip to content

Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents

The Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents - A Randomised Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07457957
Acronym
MGA
Enrollment
874
Registered
2026-03-09
Start date
2026-02-16
Completion date
2029-05-31
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent, Dysmenorrhea, Heavy Menstrual Bleeding, Menstrual Bleeding, Heavy, Menstrual Cramps, Menstrual Cycle Abnormal, Menstrual Discomfort, Menstrual Disorder, Menstrual Health, Menstrual Health Intervention, mHealth, Mobile Application

Keywords

randomized clinical trial, mHealth, Menstrual health, Adolescent, Menstrual Tracker App

Brief summary

The aim of this study is to improve menstrual health-related quality of life in adolescents by using a mobile menstrual health tracker. We will perform a randomized controlled trial to evaluate the (cost)-effectiveness of this mHealth intervention.

Detailed description

Studies have shown that menstrual health-related quality of life is influenced mainly by pain, blood loss and school/work/leisure absenteeism. We hypothesize that using a mHealth intervention designed for adolescents will increase the self-awareness of an adolescent's menstrual health, including adequate healthcare-seeking. As a result, the intervention will increase menstrual health-related quality of life. Postmenarchal adolescents aged between 12 and 22 years can be included in this study and will be randomised using 1:1 stratified randomisation in the intervention arm or control arm. Stratification factors are: age (\<16 of ≥ 16 years old), use of hormonal anticonception (yes or no) and menstrual disturbance score (Period ImPact and Pain Assessment score \<3 or ≥3). Participants in the intervention arm will be asked to track their menstrual complaints in the mobile menstrual tracker and education application daily for at least three months. Participants in the control arm will not use the mobile menstrual tracker and education application for six months. Participants in the control arm also get access to the mobile menstrual tracker and education application six months after enrollment and after the primary outcome measurement at 6-months after enrollment. The primary outcome measure is quality of life, using the PedsQL measured six months after enrollment. Secondary outcomes are school, work and leisure absenteeism, menstrual careseeking behavior, knowledge about menstrual complaints, the prevalence of suspected bleeding disorders, the prevalence of menstrual disturbance, the amount of menstrual blood loss, and societal costs. All outcomes will be measured using online questionnaires send at 6, 12 and 24 months after enrollment.

Interventions

OTHERMenstrual Tracker and Education Application

The intervention is a mobile menstrual tracker and education application developed by Amsterdam UMC researchers. The app is developed to provide insight into the users' menstrual health and contains 11 trackable domains (menstrual bleeding, pain, impact, general health, mood, urine/stool, sleep, exercise, diet, sex, notes). It is connected to an online environment where the user gets educated about normal and abnormal menstrual health.

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
12 Years to 21 Years
Healthy volunteers
Yes

Inclusion criteria

* Dutch, English, Turkish or Moroccan-Arabic speaking * Post menarche * Access to a smartphone or tablet with iOS or Android operating system

Exclusion criteria

* Amenorrhea * Pregnancy * No menstrual bleeding or withdrawel bleeding in the 3 months prior to inclusion. * Previously or currently under treatment by a health care provider for menstrual complaints

Design outcomes

Primary

MeasureTime frameDescription
Quality of Life Score6 months after enrollmentQuality of life measured at baseline and 6 months after enrollment using the validated Pediatric Quality of Life 4.0 questionnaire.

Secondary

MeasureTime frameDescription
Menstrual bleeding related quality of life6, 12, 24 months after enrollmentThe menstrual bleeding related quality of life assessed with the (adolescent) Menstrual Bleeding Questionnaire. The adolescent (\<18) or adult version of the questionnaire will be used as appropriate.
Knowledge about menstrual health6, 12 and 24 months after enrollmentThe knowledge about menstrual health will be assessed with the Menstrual Health Literacy survey.
School-, work-, and leisure absences6, 12 and 24 months after enrollmentThe impact of menstrual complaints on school, work and leisure activities will be measured using the iMTA Productivity Cost Questionnaire (iPCQ). Impact of menstrual complaints is also reported in the mobile menstrual tracker and education app.
Societal costs6, 12 and 24 months after enrollmentSocietal costs including healthcare use and prodictivity loss will be assessed using the iMTA Productivity Cost Questionnaire (iPCQ) and the iMTA Medical Consumption Questionnaire (iMCQ).
Quality of Life for cost-effectiveness calculation6, 12 and 24 months after enrollmentTo calculate the cost-effectiveness of the intervention, the quality of life assessed with the 5-level EQ-5D (EQ-5D-5L) and EQ-5D-Y-5L as appropriate as a measure for effectiveness.
Participants' experience of effectiveness6, 12 and 24 months after enrollmentThe effectiveness experienced by the participant is measured using the 1-item questionnaire Patient Global Impression of Change.
Dose of mobile menstrual tracking and education application6, 12 and 24 monthsLogdata of the mobile menstrual tracking and education application will be used to calculate the dose of the intervention received.
Menstrual disturbance6, 12 and 24 months after enrollmentThe menstrual disturbance score assessed with the Period ImPact and Pain Assessment tool (PIPPA)

Countries

Netherlands

Contacts

CONTACTEsther Domenie, MSc
MGA-studie@amsterdamumc.nl+31 6 23997219

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026